Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial Stein, E. M., DiNardo, C., Altman, J. K., Collins, R., DeAngelo, D. J., Kantarjian, H. M., Sekeres, M. A., Fathi, A. T., Flinn, I. W., Frankel, A. E., Levine, R. L., Medeiros, B. C., Patel, M. R., Pollyea, D., Roboz, G. J., Stone, R. M., Swords, R. T., Tallman, M. S., Yen, K., Attar, E. C., Xu, Q., Tosolini, A., Mei, J. M., Thakurta, A., Knight, R. D., De Botton, S. AMER SOC HEMATOLOGY. 2015
View details for Web of Science ID 000368019001075